New directions in the drug treatment of Parkinson's disease.
Identifieur interne : 004475 ( Main/Exploration ); précédent : 004474; suivant : 004476New directions in the drug treatment of Parkinson's disease.
Auteurs : J L Montastruc [France] ; O. Rascol ; J M SenardSource :
- Drugs & aging [ 1170-229X ] ; 1996.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Apomorphine (adverse effects), Apomorphine (therapeutic use), Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Neuroprotective Agents (adverse effects), Neuroprotective Agents (therapeutic use), Parkinson Disease (complications), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Selegiline (adverse effects), Selegiline (therapeutic use).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Apomorphine, Bromocriptine, Dopamine Agonists, Levodopa, Neuroprotective Agents, Selegiline.
- chemical , therapeutic use : Antiparkinson Agents, Apomorphine, Bromocriptine, Dopamine Agonists, Levodopa, Neuroprotective Agents, Selegiline.
- complications : Parkinson Disease.
- diagnosis : Parkinson Disease.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Humans.
Abstract
Parkinson's disease, a clinical syndrome with 4 cardinal features (bradykinesia, resting tremor, increased muscular rigidity and impaired postural balance), is mainly caused by the loss of dopaminergic neurons in the substantia nigra pars compacta. Although levodopa remains the 'gold standard' in the treatment of the disease, several emerging strategies are currently being developed. The first concerns new symptomatic drugs that either potentiate the effects of levodopa (e.g. slow-release preparations of levodopa, catechol-O-methyltransferase inhibitors and new dopamine agonists) or target clinical symptoms resistant to dopaminergic drugs (e.g. glutamate antagonists). The second strategy is to find drugs that are able to prevent or delay the neuronal death observed in Parkinson's disease. Several neuroprotective drugs are now in development in experimental research, but clinical trials in this area are still lacking. The development of these new drugs also depends on the validation of new clinical methodologies.
PubMed: 8877311
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001566
- to stream PubMed, to step Curation: 001525
- to stream PubMed, to step Checkpoint: 001525
- to stream Ncbi, to step Merge: 001E31
- to stream Ncbi, to step Curation: 001E31
- to stream Ncbi, to step Checkpoint: 001E31
- to stream Main, to step Merge: 004D26
- to stream Main, to step Curation: 004475
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New directions in the drug treatment of Parkinson's disease.</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Medical and Clinical Pharmacology, INSERM U317, Faculty of Medicine, University of Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Medical and Clinical Pharmacology, INSERM U317, Faculty of Medicine, University of Toulouse</wicri:regionArea><wicri:noRegion>University of Toulouse</wicri:noRegion><wicri:noRegion>University of Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1996">1996</date><idno type="RBID">pubmed:8877311</idno><idno type="pmid">8877311</idno><idno type="wicri:Area/PubMed/Corpus">001566</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001566</idno><idno type="wicri:Area/PubMed/Curation">001525</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001525</idno><idno type="wicri:Area/PubMed/Checkpoint">001525</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001525</idno><idno type="wicri:Area/Ncbi/Merge">001E31</idno><idno type="wicri:Area/Ncbi/Curation">001E31</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E31</idno><idno type="wicri:doubleKey">1170-229X:1996:Montastruc J:new:directions:in</idno><idno type="wicri:Area/Main/Merge">004D26</idno><idno type="wicri:Area/Main/Curation">004475</idno><idno type="wicri:Area/Main/Exploration">004475</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New directions in the drug treatment of Parkinson's disease.</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Medical and Clinical Pharmacology, INSERM U317, Faculty of Medicine, University of Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Medical and Clinical Pharmacology, INSERM U317, Faculty of Medicine, University of Toulouse</wicri:regionArea><wicri:noRegion>University of Toulouse</wicri:noRegion><wicri:noRegion>University of Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author></analytic><series><title level="j">Drugs & aging</title><idno type="ISSN">1170-229X</idno><imprint><date when="1996" type="published">1996</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Apomorphine (adverse effects)</term><term>Apomorphine (therapeutic use)</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Neuroprotective Agents (adverse effects)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Selegiline (adverse effects)</term><term>Selegiline (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Neuroprotective Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Neuroprotective Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease, a clinical syndrome with 4 cardinal features (bradykinesia, resting tremor, increased muscular rigidity and impaired postural balance), is mainly caused by the loss of dopaminergic neurons in the substantia nigra pars compacta. Although levodopa remains the 'gold standard' in the treatment of the disease, several emerging strategies are currently being developed. The first concerns new symptomatic drugs that either potentiate the effects of levodopa (e.g. slow-release preparations of levodopa, catechol-O-methyltransferase inhibitors and new dopamine agonists) or target clinical symptoms resistant to dopaminergic drugs (e.g. glutamate antagonists). The second strategy is to find drugs that are able to prevent or delay the neuronal death observed in Parkinson's disease. Several neuroprotective drugs are now in development in experimental research, but clinical trials in this area are still lacking. The development of these new drugs also depends on the validation of new clinical methodologies.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></noCountry><country name="France"><noRegion><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004475 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004475 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8877311
|texte= New directions in the drug treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8877311" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |